Literature DB >> 3092099

Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.

D N Pfohl, J I Allen, R L Atkinson, D S Knopman, R J Malcolm, J E Mitchell, J E Morley.   

Abstract

In summary, evidence is presented associating typically asymptomatic and reversible elevations of serum transaminase values with high daily dosages of naltrexone. Statistical significance was found only between placebo and the 300 mg dosage. Subjects aged 40 years and over were significantly more likely to develop this finding than younger subjects. All subjects with significant elevations of transaminase values in these studies took daily naltrexone dosages higher than recommended for opioid addiction. The daily dosage of naltrexone recommended for opioid addiction did not cause abnormalities of serum transaminase values in these studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092099

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN: 1046-9516


  13 in total

Review 1.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

2.  An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.

Authors:  Panagiotis Vagenas; Angela Di Paola; Maua Herme; Thomas Lincoln; Daniel J Skiest; Frederick L Altice; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2014-03-12

Review 3.  Pharmacotherapy for alcohol use disorder: current and emerging therapies.

Authors:  Robert M Swift; Elizabeth R Aston
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

Review 4.  The relationship between opioid and sugar intake: review of evidence and clinical applications.

Authors:  David J Mysels; Maria A Sullivan
Journal:  J Opioid Manag       Date:  2010 Nov-Dec

5.  Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.

Authors:  Jeanette M Tetrault; Janet P Tate; Kathleen A McGinnis; Joseph L Goulet; Lynn E Sullivan; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  Alcohol Clin Exp Res       Date:  2011-07-28       Impact factor: 3.455

6.  Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients.

Authors:  David J Mysels; Suzanne K Vosburg; Ileana Benga; Frances R Levin; Maria A Sullivan
Journal:  J Opioid Manag       Date:  2011 Jan-Feb

7.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 8.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats.

Authors:  Carsten K Nielsen; Jeffrey A Simms; Haley B Pierson; Rui Li; Surendra K Saini; Subramaniam Ananthan; Selena E Bartlett
Journal:  Biol Psychiatry       Date:  2008-09-06       Impact factor: 13.382

10.  Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.

Authors:  Andrea King; Dingcai Cao; Catherine Vanier; Tracie Wilcox
Journal:  Alcohol Clin Exp Res       Date:  2009-03-19       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.